Fresenius SE & Co. KGaA

Fresenius SE & Co. KGaA: Fresenius raises outlook for fiscal year 2024

Fresenius SE & Co. KGaA: Robert Möller, buy

Fresenius SE & Co. KGaA: Pierluigi Antonelli, buy

Fresenius SE & Co. KGaA: Sara Hennicken, buy

Fresenius SE & Co. KGaA: Michael Sen, buy

Fresenius SE & Co. KGaA: Announcement of the Convening of the General Meeting in Frankfurt am Main on 17.05.2024 according to article 121 AktG (German Stock Companies Act) with the objective of Europe-wide distribution

Fresenius SE & Co. KGaA: Dr. Frank Appel, buy

Fresenius SE & Co. KGaA: Fresenius retains relief payments for hospitals of up to €300 million (from the current perspective) and is therefore subject to a ban on dividends and bonuses for 2023

Fresenius SE & Co. KGaA: Dr. Michael Moser, buy

Fresenius SE & Co. KGaA: Sara Hennicken, buy

Fresenius SE & Co. KGaA: Michael Sen, buy

Fresenius SE & Co. KGaA: Announcement of the Convening of the General Meeting in Frankfurt am Main on 17.05.2023 according to article 121 AktG (German Stock Companies Act) with the objective of Europe-wide distribution

Fresenius SE & Co. KGaA: Outlook 2023 – Fresenius advances with deconsolidation of Fresenius Medical Care by changing its legal form into a German stock corporation (Aktiengesellschaft)

Fresenius SE & Co. KGaA: Fresenius SE & Co. KGaA confirms review of deconsolidation of Fresenius Medical Care through change of legal form into a stock corporation

Helen Giza is the new CEO of Fresenius Medical Care; Dr. Carla Kriwet leaves the company

Fresenius SE & Co. KGaA: Dr. Francesco De Meo, buy